Last updated: October 8, 2024
Sponsor: Taipei Medical University Hospital
Overall Status: Completed
Phase
2
Condition
Stroke
Occlusions
Cardiac Ischemia
Treatment
Placebo
Menthol
Clinical Study ID
NCT05877079
N202302006
Ages > 20 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Acute ischemic stroke patients, stroke time within one week, those who are legallyof age at the time of signing the consent form, NIHSS 4-20, patients who cancooperate with treatment, Self or agent agrees to sign the consent form.
Exclusion
Exclusion Criteria:
- NIHSS score does not meet, mRS=5, patients who cannot cooperate, moderate to severebrain trauma, pregnant women, uremia, liver cirrhosis, heart failure with pulmonaryedema and coagulation dysfunction, epilepsy, alcohol, drug abuse. Participants wereranked by the investigator as unsuitable for the study.
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2
Study Start date:
May 26, 2023
Estimated Completion Date:
June 06, 2024
Study Description
Connect with a study center
Taipei Medical University Hospital
Taipei,
TaiwanSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.